These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
658 related articles for article (PubMed ID: 25877505)
1. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue. Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926 [TBL] [Abstract][Full Text] [Related]
3. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases. Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141 [TBL] [Abstract][Full Text] [Related]
4. Soluble CD163: A Novel Biomarker with Diagnostic and Therapeutic Implications in Autoimmune Diseases. Zhou D; Wang Y; Chen LU; Zhang W; Luan J J Rheumatol; 2016 Apr; 43(4):830. PubMed ID: 27037247 [No Abstract] [Full Text] [Related]
5. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease. Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients. Tanimura H; Mizuno K; Okamoto H Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):99-105. PubMed ID: 26278688 [TBL] [Abstract][Full Text] [Related]
7. CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Nakayama W; Jinnin M; Makino K; Kajihara I; Makino T; Fukushima S; Sakai K; Inoue Y; Ihn H Eur J Dermatol; 2012; 22(4):512-7. PubMed ID: 22576016 [TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Yuan L; Yao L; Zhao L; Xia L; Shen H; Lu J Clin Exp Rheumatol; 2013; 31(3):428-32. PubMed ID: 23485578 [TBL] [Abstract][Full Text] [Related]
9. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688 [TBL] [Abstract][Full Text] [Related]
10. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Baeten D; Møller HJ; Delanghe J; Veys EM; Moestrup SK; De Keyser F Arthritis Rheum; 2004 May; 50(5):1611-23. PubMed ID: 15146432 [TBL] [Abstract][Full Text] [Related]
11. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653 [TBL] [Abstract][Full Text] [Related]
13. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis]. Chen F; Shu XM; Wang DX; Xie Y; Wang GC Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422 [TBL] [Abstract][Full Text] [Related]
15. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782 [TBL] [Abstract][Full Text] [Related]
16. Utility of Macrophage-activated Marker CD163 for Diagnosis and Prognosis in Pulmonary Tuberculosis. Suzuki Y; Shirai M; Asada K; Miwa S; Karayama M; Nakamura Y; Inui N; Shirai T; Hayakawa H; Baba S; Suda T Ann Am Thorac Soc; 2017 Jan; 14(1):57-64. PubMed ID: 27684274 [TBL] [Abstract][Full Text] [Related]
17. Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis. Greisen SR; Moller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Jørgensen A; Hvid M; Deleuran B Clin Exp Rheumatol; 2011; 29(4):689-92. PubMed ID: 21813065 [TBL] [Abstract][Full Text] [Related]
18. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs. Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601 [TBL] [Abstract][Full Text] [Related]
19. Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy. Kondelkova K; Krejsek J; Borska L; Fiala Z; Hamakova K; Andrys C Allergol Immunopathol (Madr); 2013; 41(3):158-62. PubMed ID: 22765877 [TBL] [Abstract][Full Text] [Related]
20. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]